An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects
Language English Country Germany Media print-electronic
Document type Journal Article
Grant support
18-09502S
Czech Science Foundation
1611/14
Israel Science Foundation
LTC17003
Ministry of Education of the Czech Republic
- Keywords
- 3D spheroids, DNA damage, anticancer agents, epigenetic effects, platinum prodrugs,
- MeSH
- Biological Transport MeSH
- Cisplatin chemistry pharmacology MeSH
- Epigenesis, Genetic * MeSH
- Phenylbutyrates chemistry pharmacology MeSH
- Histone Deacetylases metabolism MeSH
- Caprylates chemistry pharmacology MeSH
- Humans MeSH
- DNA Methylation MeSH
- Cell Line, Tumor MeSH
- DNA Damage * MeSH
- Prodrugs chemistry pharmacology MeSH
- Cell Proliferation drug effects MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Drug Screening Assays, Antitumor MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Cisplatin MeSH
- Phenylbutyrates MeSH
- Histone Deacetylases MeSH
- Caprylates MeSH
- octanoic acid MeSH Browser
- Prodrugs MeSH
- Antineoplastic Agents MeSH
Dual- or multi-action PtIV prodrugs represent a new generation of platinum anticancer drugs. The important property of these PtIV prodrugs is that their antitumor action combines several different mechanisms owing to the presence of biologically active axial ligands. This work describes the synthesis and some biological properties of a "triple-action" prodrug that releases in cancer cells cisplatin and two different epigenetically acting moieties, octanoate and phenylbutyrate. It is demonstrated, with the aid of modern methods of molecular and cellular biology and pharmacology, that the presence of three different functionalities in a single molecule of the PtIV prodrug results in a selective and high potency in tumor cells including those resistant to cisplatin [the IC50 values in the screened malignant cell lines ranged from as low as 9 nm (HCT-116) to 74 nm (MDA-MB-231)]. It is also demonstrated that cellular activation of the PtIV prodrug results in covalent modification of DNA through the release of the platinum moiety accompanied by inhibition of the activity of histone deacetylases caused by phenylbutyrate and by global hypermethylation of DNA by octanoate. Thus, the PtIV prodrug introduced in this study acts as a true "multi-action" prodrug, which is over two orders of magnitude more active than clinically used cisplatin, in both 2D monolayer culture and 3D spheroid cancer cells.
Institute for Drug Research School of Pharmacy The Hebrew University Jerusalem 91120 Israel
Institute of Biophysics Czech Academy of Sciences Kralovopolska 135 CZ 61265 Brno Czech Republic
References provided by Crossref.org